DRMAW 0.01 Dermata Therapeutics, Inc.
| Range: | 0.0088-0.0088 | Vol Avg: | 0 | Last Div: | 0 | Changes: | 0 |
| Beta: | 0.78 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Fri Aug 13 2021 | Empoloyees: | 8 | ||
| CUSIP: | 249845116 | CIK: | 0001853816 | ISIN: | US2498451168 | Country: | US |
| CEO: | Mr. Gerald T. Proehl | Website: | https://www.dermatarx.com | ||||
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. It is also developing DMT410 for the treatment of hyperhidrosis and aesthetic conditions. The company was founded in 2014 and is headquartered in San Diego, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow